Wegovy 0.5mg: what happens at this dose and how long you stay on it

Why does the Wegovy schedule start so low before reaching 0.5mg?

Semaglutide slows gastric emptying and acts on appetite centres in the brain, which is exactly what makes it effective, but that same mechanism is why some people feel nauseous, particularly when first starting or after a dose change. The 0.25mg opening dose exists mainly to give your body time to adjust. It is not expected to produce significant weight loss on its own; the job it does is settling your digestive system so that subsequent steps are better tolerated.

When you move to 0.5mg, you are taking the first real step toward meaningful appetite suppression. Many people describe the shift as noticeable: meals feel filling faster, the pull toward between-meal snacking quietens. The full Wegovy dose schedule covers each step in detail, but the broad pattern is four weeks at each level, with a prescriber deciding whether to proceed based on how you are tolerating the current dose.

There is no clinical benefit to skipping the early rungs. If you are transferring to Wegovy from another medicine, or restarting after a break, your prescriber will determine the appropriate starting point, sometimes that means returning to the 2.5mg dose that some people use to restart or re-establish tolerance regardless of where you were before.

What side effects are most common when you first reach 0.5mg?

The most frequently reported effects at this stage are gastrointestinal: nausea, loose stools or constipation, indigestion, burping and a general feeling of fullness that can occasionally tip into discomfort. Fatigue and mild headaches are also reported. These effects tend to be most noticeable in the first week or two after each dose increase, then ease as your body adapts.

A few practical things that often help: eating smaller portions slowly, avoiding very fatty or spicy meals during the adjustment window, and drinking enough water throughout the day. If you are starting a new dose on a Friday, be aware that the first few days can land over a weekend, some people plan their injection day around that. Equally, if you know a big occasion or travel falls in the week after a planned dose increase, it is worth flagging to your prescriber beforehand.

The MHRA's Yellow Card scheme is the right channel for reporting any side effects you experience on a prescription medicine. If you develop severe, persistent stomach pain (particularly pain that radiates toward your back) seek medical help promptly; this is the symptom pattern associated with acute pancreatitis, which the MHRA highlighted in a 2026 Drug Safety Update for GLP-1 medicines. For anything less acute, your prescribing team is your first port of call. The nume support team is available seven days a week if you have questions between consultations.

Who is likely to be at the 0.5mg step, and how does it relate to the licensed eligibility criteria?

Wegovy's UK licence covers adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. The 0.5mg dose is simply one point in a journey through that licensed treatment, you would not be at 0.5mg without already having met the criteria and received a prescription.

On the NHS, Wegovy is available through specialist weight management services under NICE's technology appraisal TA875, which sets its own eligibility thresholds and requires multidisciplinary support. NHS access remains limited and waiting lists can be long. Private treatment through a GPhC-registered online pharmacy is an alternative route for people who meet the clinical criteria but are not waiting for an NHS referral. You can read more about where to get Wegovy in the UK if you are still weighing your options.

For people already established on treatment, the 0.5mg step is a routine phase rather than a decision point. The more significant conversations with a prescriber tend to happen around the higher maintenance doses, including the considerations that come with moving through the 1.5mg stage on the way to full maintenance.

What comes after 0.5mg, and how do you know it's time to move up?

After approximately four weeks at 0.5mg, the next step is 1.0mg, then 1.7mg, then the standard 2.4mg maintenance dose. The MHRA also approved a 7.2mg dose in January 2026 for adults who need it, initially given as three 2.4mg pens weekly, with a dedicated single-dose pen approved in April 2026 for adults with a BMI of 30 or above. You can find out more about what the 5mg Wegovy pen involves and who it is intended for, as the higher-dose options have their own clinical considerations and are not appropriate for everyone.

The move from 0.5mg to 1.0mg is not automatic. A prescriber needs to confirm you are tolerating the current dose adequately and that continuing is clinically appropriate. At nume, every repeat order goes through a fresh clinical review by a GPhC-registered prescriber before anything is dispensed, no prescription is issued on autopilot. If you have questions about the cost involved in ongoing private treatment, the treatment page sets out what is included in a single transparent price.

The trial data published in the STEP 1 study in the New England Journal of Medicine showed an average weight reduction of around 15% over 68 weeks at the 2.4mg maintenance dose. That outcome builds through each step of the schedule, 0.5mg is part of the foundation, not where the results are measured.